Ying Cao (@NeuralGrndState) header
Ying Cao (@NeuralGrndState) profile picture

My rubbish research: the core property of cancer cell is neural stemness, which determines pluripotency&tumorigenicity. EMT/MET/EndMT are groundless 'concepts'

Joined January 2022
Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)Photo by Ying Cao (@NeuralGrndState)
I would love to see more true innovation in clinical oncology driven by science. Incremental advances with “me too” combinations have defined much of what we see at the biggest meetings. Careers are made and propagated without true breakthroughs.
2
2
2
28
2,333
I'm surprised by the misleading viewpoint or ignorance of the paper below because they failed to consider cancer-cell intrinsic neural stemness signaling&neural stemness as the core property of cancer cells @Cancer_Cell 'Neural signaling.., is not intrinsically tumor-promoting'
Context dependency in cancer neuroscience dlvr.it/TTcx3F
1
1
1
38
This sounds like a good book countering simplistic & naive notions. “So long as we insist that cells are computers and genes are their code,” writes Ball, life might as well be “sprinkled with invisible magic”. But, reality “is far more interesting and wonderful” 1/3
22
58
9
296
40,895
Small cell lung cancer (SCLC) may evade natural killer (NK) cells through a simple but elegant physical mechanism—hiding its own adhesion ligand. A new Cell Death & Disease (2026) study identifies NCAM1 (CD56) as a dual regulator of tumor stemness and NK cell immune evasion in SCLC. Rather than acting solely as a diagnostic marker, NCAM1 actively promotes immune resistance through cis-interactions with L1CAM and enhances membrane repair via CHMP4B, enabling tumor cells to survive cytotoxic attack. NCAM1 marks aggressive, stem-like SCLC Analysis of resected human SCLC specimens showed that approximately 80% of tumors expressed NCAM1. High NCAM1 levels were associated with significantly worse overall survival and progression-free survival, higher nodal stage, and enrichment of stem-cell gene signatures, including SOX2 and CD133. Functional experiments confirmed causality. Silencing NCAM1 reduced expression of stemness markers (SOX2, CD133, ABCG2), decreased tumorsphere formation, and reduced the proportion of CD24⁺CD44⁺ and SOX2⁺ cells. Conversely, NCAM1 overexpression enhanced self-renewal and stem-like phenotypes. Escaping NK-cell killing The authors next asked whether NCAM1 influences innate immune surveillance. Expanded CD56⁺ NK cells efficiently killed NCAM1-deficient SCLC cells, whereas NCAM1-overexpressing cells became markedly more resistant across multiple effector-to-target ratios. Live-cell imaging and apoptosis assays demonstrated delayed tumor lysis without impairing NK-cell perforin or granzyme production, indicating that the defect lies within tumor–NK interactions rather than NK-cell activation itself. Scanning electron microscopy provided a striking visualization: NCAM1-deficient tumor cells formed stable immune synapses with NK cells, while NCAM1-high cells rarely established tight contacts. NK cells exposed to NCAM1-high tumors also secreted less CXCL9 and CXCL10, suggesting impaired recruitment of additional cytotoxic lymphocytes. A clever immune-evasion strategy The most novel finding involves cis-binding. NCAM1 binds L1CAM on the same tumor cell surface, masking L1CAM epitopes that would otherwise engage CD56 on NK cells. This cis-interaction prevents efficient tumor–NK conjugate formation and reduces immune-synapse assembly. Importantly, the effect occurred only when NCAM1 and L1CAM were expressed on the same cell, highlighting a true cis-regulatory mechanism rather than intercellular competition. Surviving after contact Even when NK cells successfully attached, NCAM1 provided a second defense. Proteomic analyses identified CHMP4B and TSG101, components of the ESCRT membrane-repair machinery, as NCAM1-interacting partners. CHMP4B overexpression promoted tumorsphere formation and resistance to NK-mediated cytotoxicity, while CHMP4B knockdown impaired both phenotypes. These findings suggest that NCAM1 recruits ESCRT components to repair perforin-induced membrane damage, allowing tumor cells to survive immune attack. Clinical relevance Multiplex immunofluorescence demonstrated that tumors with high NCAM1 and high CHMP4B contained fewer infiltrating NKG2D⁺GZMB⁺ cytotoxic immune cells, exhibited greater spatial exclusion of NK cells, and were associated with significantly poorer survival. Take-home message This study expands the role of NCAM1 beyond a diagnostic marker for SCLC. NCAM1 simultaneously: promotes cancer stemness, prevents NK-cell immune-synapse formation through cis-NCAM1/L1CAM interactions, and enhances ESCRT-mediated membrane repair via CHMP4B. Targeting the NCAM1–CHMP4B axis may therefore overcome both stemness and innate immune resistance, offering a promising therapeutic strategy for one of the most treatment-resistant lung cancers. Reference Qi J, Sun H, Yang Y, et al. NCAM1 potentiates small cell lung cancer stemness and resistance to NK cell-mediated cytotoxicity. Cell Death & Disease. 2026.
1
2
164
If blood cells are direct descendant cells of unicellular ancestors during evolution, as revealed by these studies, the entire history of animal evolution and all knowledge of dev. biol. so far needs to be rewritten or overturned pnas.org/doi/10.1073/pnas.25… ashpublications.org/blood/ar…
1
2
83
As Max Planck said, "Science advances one funeral at a time."
1
6
266
“Biology is Hard” is a versatile concept. It is a simple truth - it IS hard. It is a useful retort to people who treat its challenges cavalierly. But it is also an excuse - used to rationalize rejecting new approaches in favor of repeating the same mistakes and refusing to correct structural problems in the field that have led to repeated failures.
4
16
1
110
13,899
The Cancer Research Enterprise Has a Scale Problem My latest essay examines why the most celebrated advances in oncology still leave us far from substantially reducing the burden of cancer. open.substack.com/pub/rebuil…
7
5
3
33
4,622
Another take home point of my comments is that radical changes will be needed if we actually want to make a dent in cancer through developing new drugs. According to Grok (ht @Dr_Alchemy), the 10 most widely used cancer drugs today are: • Methotrexate (1953) • Cyclophosphamide (1959) • 5-Fluorouracil (1962) • Doxorubicin (1974) • Cisplatin (1978) • Carboplatin (1989) • Paclitaxel (1992) • Gemcitabine (1996) • Docetaxel (1996) • Oxaliplatin (2002) These are largely small tweaks and variations on drugs that were introduced 50–100 years ago. This is what oncologists prescribe despite decades of advances in molecular biology and genomics, and billions upon billions of dollars spent on cancer research. Without a coordinated effort to overhaul the regulatory system and rethink how drugs are actually developed, tested, approved, and manufactured, the celebrations at conferences like ASCO will continue to be small potatoes relative to the scale of the cancer problem.
After decades of work and billions of dollars, this is what passes for a revolution in cancer research. This drug is being hyped to no end on social media. At the oncology conference, there is a standing ovation from a crowd of 40,000 doctors and industry people celebrating it as a major breakthrough and the defining achievements of cancer research over the last decade. The scientists behind it will win a Nobel Prize. What exactly is the achievement? A drug that extends life by six months in less than 10% of cancer patients. The cumulative R&D costs run into the billions of dollars. The drug is not a cure and pancreatic cancer mortality does not change. Resistance develops and more drugs need to be developed. When those drugs are hailed as breakthroughs, resistance develops again. Everyone in the industry knows this approach does not scale as a durable solution. It is not a cure for cancer. This work follows a narrow line of thinking based on oncogene theories that has consumed enormous amounts of federal funding and biotech R&D for four decades. At the same time, environmental factors, prevention, detection, the root causes of cancer, tumor evolution, diet, exercise, and many other areas of cancer research were neglected. Any criticism of this model is immediately met by a coalition of interests invested in preserving it. Academic researchers, pharmaceutical companies, investors, journals, science media, professional societies, consultants, patient advocacy groups who have been told there is no other way, and online activists all have incentives tied to the existing model. Critics are accused of attacking patients, opposing progress, or undermining science itself. Cancer patients become shields in a bigger issue that is really about the performance of the cancer research enterprise. After decades of effort and billions of dollars, this is what the cancer establishment is giving itself a standing ovation for.
11
2
1
30
4,805
People that think like this guy are a major part of the problem. Dunking implies there is an easy target and a helpless defender. In reality, there is an entire biomedical establishment defending this model. Just look at the negative reaction my post generated. I am questioning whether a strategy built around developing expensive therapies for late-stage disease one mutation at a time scales as a public health solution to cancer. Meanwhile, prevention and early detection remain comparatively small areas of focus that have attracted far fewer resources. The GLP-1 comparison actually illustrates the point because those drugs do scale. At the same time, I am a strong advocate of diet, exercise, and disease prevention. In fact, I wish more of those principles were studied and applied in the context of cancer. The oncogene theory of cancer has dominated the field for roughly half a century. Billions, or maybe trillions, of dollars have been invested in pursuing it. Hundreds of thousands, if not millions, of people now have careers, companies, institutions, and financial interests tied to its continuation. That does not make it wrong. But it does make it worth asking whether the returns have been commensurate with the investment and whether alternative approaches deserve more attention.
Replying to @LocasaleLab
There's a 20-30 year window to prevent heart disease, obesity, and diabetes too. I don't see you crying about GLP-1s. Can't believe you're dunking on a therapy that doubles the lifespan of someone battling cancer. Wild.
6
3
18
3,332
After decades of work and billions of dollars, this is what passes for a revolution in cancer research. This drug is being hyped to no end on social media. At the oncology conference, there is a standing ovation from a crowd of 40,000 doctors and industry people celebrating it as a major breakthrough and the defining achievements of cancer research over the last decade. The scientists behind it will win a Nobel Prize. What exactly is the achievement? A drug that extends life by six months in less than 10% of cancer patients. The cumulative R&D costs run into the billions of dollars. The drug is not a cure and pancreatic cancer mortality does not change. Resistance develops and more drugs need to be developed. When those drugs are hailed as breakthroughs, resistance develops again. Everyone in the industry knows this approach does not scale as a durable solution. It is not a cure for cancer. This work follows a narrow line of thinking based on oncogene theories that has consumed enormous amounts of federal funding and biotech R&D for four decades. At the same time, environmental factors, prevention, detection, the root causes of cancer, tumor evolution, diet, exercise, and many other areas of cancer research were neglected. Any criticism of this model is immediately met by a coalition of interests invested in preserving it. Academic researchers, pharmaceutical companies, investors, journals, science media, professional societies, consultants, patient advocacy groups who have been told there is no other way, and online activists all have incentives tied to the existing model. Critics are accused of attacking patients, opposing progress, or undermining science itself. Cancer patients become shields in a bigger issue that is really about the performance of the cancer research enterprise. After decades of effort and billions of dollars, this is what the cancer establishment is giving itself a standing ovation for.
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously. Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here. This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group. If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.
118
33
35
225
225,403
Origin of stem cell research (3/175) Our story begins long before the dawn of modern medicine. It starts with mysterious tumours – the teratomas. For centuries, physicians reported these unusual growths. Masses that sometimes contained gut, skin, hair, bone or even teeth! They looked disturbing, almost unreal, and often inspired fear and fascination in equal measure. The word teratoma comes from Greek. teras (τέρας) meaning monster or marvel oma (ὄμα) meaning tumour Teratoma literally means: “monstrous tumour”. #OriginOfStemCells #Teratoma
1
1
13
787
Science is about pursuit of truth that is generally absolute in nature. The path to uncover truth takes many twists and turns often with surprising findings that open our eyes and shine light on things less obvious. The more I learn in science and medicine the more I realize how little we all really know and I think accepting when one is wrong about something allows growth and progress. Sometimes different people looking at a problem from different perspectives reveals parts of the truth but a big puzzle comes together when people collaborate for greater good. In the end scientific truth doesn’t change whether we accept it or not. Freedom of scientific inquiry: reclaiming space for controversy nature.com/articles/s41577-0… @VirusesImmunity
2
4
9
626
Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging collaboration. fiercebiotech.com/biotech/gi…
2
3
3
20
12,888
Ok this figure is pretty intimidating...
30
54
50
445
211,322
China’s biomedical research system largely copied the American one, but it copied many of the worst parts. The obsession with h-index scores, citation counts, and journal impact factors was imported and in many places made even more extreme. What was not imported as easily were the deeper traditions of creativity and intellectual independence that helped build the original system. Meanwhile the reproducibility crisis in the biomedical literature sits there unresolved. Nature’s stream of feel-good coverage about China should be read with skepticism. The publisher has offices there and is aggressively expanding in the Chinese market. They see a growing stream of publishing and subscription revenue. The journal’s business model depends on extracting fees from that system, and the incentives for flattering coverage become obvious.
6
13
1
112
17,612
If you are not required to publish for academic promotion, you do not have to keep feeding this distorted system. Write your views on other platforms. Present your analyses at conferences and open them to discussion. The reality is simple: if you do not have connections, publishing in a prestigious journal is already difficult. If you do not have money, publishing even in lower-tier journals is becoming difficult. The system increasingly rewards networks and funding rather than ideas. Social media platforms may have turned into echo chambers, but for now they remain one of the few places where ideas can still be debated openly. At least you are not waiting at an editor’s door or depending on a reviewer’s mood. The channels that control how knowledge circulates have narrowed so much that even our sense of fairness has been minimized. Still, speaking up, refusing to bend, and keeping the debate alive remains possible.
Peer review was supposed to be science’s quality filter, but somewhere along the way it started acting more like a bouncer who only lets in the regulars. It’s slow, it tends to favor established labs and familiar names, and it gets uncomfortable around anything too unconventional. Papers loaded with mountains of data tend to cruise through, while bold ideas that actually challenge the consensus get stuck in limbo or turned away at the door. The irony is that where a paper gets published almost never determines its real worth. What actually matters is what the scientific community does with it afterward, whether people cite it, argue with it, build on it, or use it to blow up a long-held assumption. That’s where the value lives, not in the journal’s logo. A major survey a few years back found that roughly 70% of researchers think the current system is fundamentally broken, and it’s not hard to see why. Publicly funded research hides behind paywalls, editors chase whatever topic is hot that month, and the whole incentive structure pushes toward safe bets over genuinely risky and potentially important work. Science has always been complicated and deeply human and full of ego and inertia, but the conversation is shifting.
Readers added context they thought people might want to know
La portada es falsa. Las fechas de la portada de la imagen corresponden a la edición doble de vacaciones. economist.com/weeklyedition/…
6
18
1,976
Pancreatic cancers with a KRAS mutation: 90% Approved KRAS inhibitors in pancreatic cancer: 0 KRAS inhibitors in trials for pancreatic cancer: 10 There are lots of results due this year, including (most excitingly) for Daraxonrasib, which has a phase 3 readout
Emerging landscape of KRAS inhibitors in cancer treatment @Cancer_Cell doi.org/10.1016/j.ccell.2026… 👏great review 👉Tsunami of new drugs and oppertunities @myESMO @ASCO
4
51
3
255
50,259